A citation-based method for searching scientific literature

Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Times Cited: 502



Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen, Heikki V Huikuri, Isabelle Johansson, Peter Jüni, Maddalena Lettino, Nikolaus Marx, Linda G Mellbin, Carl J Östgren, Bianca Rocca, Marco Roffi, Naveed Sattar, Petar M Seferović, Miguel Sousa-Uva, Paul Valensi, David C Wheeler. Eur Heart J 2020
Times Cited: 921




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
4


Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Nick S R Lan, Bu B Yeap, P Gerry Fegan, Gillian Green, James M Rankin, Girish Dwivedi. Int J Cardiovasc Imaging 2021
2

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John P H Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2021
2

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito. Cardiovasc Diabetol 2021
9

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Evdoxia Bletsa, Sebastien Filippas-Dekouan, Christina Kostara, Panagiotis Dafopoulos, Aikaterini Dimou, Eleni Pappa, Styliani Chasapi, Georgios Spyroulias, Anastasios Koutsovasilis, Eleni Bairaktari,[...]. J Clin Endocrinol Metab 2021
1

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
2


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Vishnu Vardhan Garla, Javed Butler, Lillian F Lien. Curr Cardiol Rep 2021
0

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M S Sarwar,[...]. Heart Fail Rev 2021
0

SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies.
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, Paolo Chiodini, Annalisa Capuano, Giuseppe Paolisso. Pharmacol Res 2021
1